MOv18 IgE, the first IgE antibody to enter the clinic, targets the cancer-associated antigen Folate Receptor-alpha (FRα), known to be overexpressed in several cancers including ovarian, endometrial, Triple-negative breast cancer and lung [13–17]. Here, IGHE is linked to cancer.